TEVIMBRA ist in den USA für die Erstlinienbehandlung von fortgeschrittenem Plattenepithelkarzinom der Speiseröhre in Kombination mit Chemotherapie zugelassen
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 05 2025
0mins
Should l Buy ?
Source: Businesswire
FDA Approval of TEVIMBRA: BeiGene, Ltd. announced the FDA's approval of its drug TEVIMBRA® for first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) expressing PD-L1, based on significant survival improvements shown in clinical trials.
Company Name Change and Commitment: The company plans to change its name to BeOne Medicines Ltd., emphasizing its dedication to developing innovative cancer therapies and improving access to treatments for patients globally.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
